Citius Pharmaceuticals, Inc. (CTXR) Form 10-Q — May 15, 2026
Citius Pharmaceuticals reported $5.6 million in revenue for the six months ended March 31, 2026, driven by the commercial launch of its oncology product LYMPHIR in December 2025. This marks the first significant revenue generation for the company, with gross margins of approximately 80% on product sales. The company recorded a net loss of $37.5 million for the period, heavily impacted by a $19.7 million contract cancellation fee from a contract manufacturing organization. General and administrative expenses surged to $32.1 million, reflecting the one-time charge and ongoing operational costs, while stock-based compensation totaled $8.1 million.
Key figures
- Revenue
- 5611409
- Total Debt
- 17650000
- Cash Position
- 4590174
- Cash Runway End
- November 2026
- Shares Outstanding
- 27452570
- Stock Based Compensation
- 8068502
- Contract Cancellation Fee
- 19733307
- Gain On Sale Of NJNet Operating Losses
- 3833277
Price after filing
Close on the filing date to close N calendar days later (from $0.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.